Search Results - "Mamidi, Rao N.V.S."

De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes by Dallas, Shannon, Sensenhauser, Carlo, Batheja, Ameesha, Singer, Monica, Markowska, Maria, Zakszewski, Cindy, Mamidi, Rao N V S, McMillia, Michael, Han, Chao, Zhou, Honghui, Silva, Jose

“…Inflammatory diseases such as rheumatoid arthritis and psoriasis are characterized by increases in circulating cytokines, which play an important role in…”
Get more information

Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib by De Zwart, Loeckie, Snoeys, Jan, Jacobs, Frank, Li, Lilian Y., Poggesi, Italo, Verboven, Peter, Goris, Ivo, Scheers, Ellen, Wynant, Inneke, Monshouwer, Mario, Mamidi, Rao N. V. S.

“…Erdafitinib is a potent oral pan‐fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast…”
Get full text

Lack of Effect of Sucralfate on the Absorption and Pharmacokinetics of Rosiglitazone by Rao, Mamidi N.V.S., Mullangi, Ramesh, Katneni, Kasiram, Ravikanth, Bhamidipati, Babu, Aravind P., Rani, Usha P., Naidu, M.U.R., Srinivas, Nuggehally R., Rajagopalan, Ramanujam

“…The aim of the present study was to investigate the effect of sucralfate pretreatment on the pharmacokinetics of rosiglitazone following a single oral dose in…”
Get full text

Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents by Madhavan, Gurram R, Chakrabarti, Ranjan, Kumar, Sunil K.B, Misra, Parimal, Mamidi, Rao N.V.S, Balraju, V, Kasiram, Katneni, Babu, Ravi K, Suresh, Juluri, Lohray, Braj B, Lohray, Vidya B, Iqbal, Javed, Rajagopalan, Ramanujam

“…We report here the synthesis of a series of 5-[4-[2-[substituted phthalazinones-2(or 4)yl]ethoxy]phenylmethyl]thiazolidine-2,4-diones and…”
Get full text

Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives by MADHAVAN, Gurram R, CHAKRABARTI, Ranjan, RAJAGOPALAN, Ramanujam, VIKRAMADITHYAN, Reeba K, MAMIDI, Rao N. V. S, BALRAJU, V, RAJESH, B. M, MISRA, Parimal, KUMAR, Sunil K. B, LOHRAY, Braj B, LOHRAY, Vidya B

“…A series of pyrimidinone derivatives of thiazolidinediones were synthesized. Their biological activity were evaluated in insulin resistant, hyperglycemic and…”
Get full text

Safety, Tolerability, and Pharmacokinetics of a Capsule Formulation of DRF-1042, a Novel Camptothecin Analog, in Refractory Cancer Patients in a Bridging Phase I Study by Chatterjee, Arani, Digumarti, Raghunadharao, Katneni, Kasiram, Upreti, Vijay V., Mamidi, Rao N. V. S., Mullangi, Ramesh, Surath, Anjna, Srinivas, Maddali L., Uppalapati, Srihari, Jiwatani, Sangeeta, Srinivas, Nuggehally R.

“…The purpose of this bridging phase I study was to characterize the toxicity, pharmacokinetics, and antitumor effects of a capsule formulation of DRF‐1042, a…”
Get full text

Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment by Alamer, Ahmad, Te, Charisse, Fazel, Maryam T

Get full text

In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans by Francke, Stephan, Mamidi, Rao N. V. S., Solanki, Bhavna, Scheers, Ellen, Jadwin, Andrew, Favis, Reyna, Devineni, Damayanthi

“…O‐glucuronidation is the major metabolic elimination pathway for canagliflozin. The objective was to identify enzymes and tissues involved in the formation of…”
Get full text

Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats by Mamidi, Rao N.V.S., Mullangi, Ramesh, Kota, Jagannath, Bhamidipati, Ravikanth, Khan, Ansar A., Katneni, Kasiram, Datla, Srinivasaraju, Singh, Sunil K., Rao, Koteswar Y., Seshagiri Rao, C., Srinivas, Nuggehally R., Rajagopalan, Ramanujam

“…This study demonstrates the utility of an in vitro – in vivo correlative approach in the selection and optimization of a prodrug candidate of celecoxib (CBX),…”
Get full text

Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors by Snyder, Linda A., Damle, Rajendra, Patel, Shefali, Bohrer, Jared, Fiorella, Anna, Driscoll, Jenny, Hawkins, Rebecca, Stratton, Christopher F., Manning, Carol D., Tatikola, Kanaka, Tryputsen, Volha, Packman, Kathryn, Mamidi, Rao N.V.S.

“…Abstract Patients with prostate cancer whose tumors bear deleterious mutations in DNA-repair pathways often respond to PARP inhibitors. Studies were conducted…”
Get full text

Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor by Scheers, Ellen, Borgmans, Carine, Keung, Chi, Bohets, Hilde, Wynant, Inneke, Poggesi, Italo, Cuyckens, Filip, Leclercq, Laurent, Mamidi, Rao N. V. S.

“…This article describes in vivo biotransformation and disposition of erdafitinib following single oral dose of 3 H-erdafitinib and 14 C-erdafitinib to intact…”
Get full text

Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE) by Saad, Fred, Chi, Kim N., Shore, Neal D., Graff, Julie N., Posadas, Edwin M., Lattouf, Jean-Baptiste, Espina, Byron M., Zhu, Eugene, Yu, Alex, Hazra, Anasuya, De Meulder, Marc, Mamidi, Rao N. V. S., Bradic, Branislav, Francis, Peter, Hayreh, Vinny, Rezazadeh Kalebasty, Arash

“…Purpose To assess the safety and pharmacokinetics and determine the recommended phase 2 dose (RP2D) of niraparib with apalutamide or abiraterone acetate plus…”
Get full text

Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin by De Jonghe, Sandra, Proctor, Jim, Vinken, Petra, Feyen, Bianca, Wynant, Inneke, Marien, Dirk, Geys, Helena, Mamidi, Rao N.V.S., Johnson, Mark D.

“…•Canagliflozin, an SGLT2 inhibitor for treatment of diabetes, caused tumors in rats.•Leydig cell tumors were attributed to increased luteinizing…”
Get full text

Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug–Drug Interaction Study by Poggesi, Italo, Li, Lilian Y., Jiao, James, Hellemans, Peter, Rasschaert, Freya, de Zwart, Loeckie, Snoeys, Jan, De Meulder, Marc, Mamidi, Rao N. V. S., Ouellet, Daniele

“…Background and Objectives Erdafitinib, an oral selective pan-fibroblast growth factor receptor (FGFR) kinase inhibitor, is primarily metabolized by cytochrome…”
Get full text

In vitro and physiologically‐based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin by Mamidi, Rao N. V. S., Dallas, Shannon, Sensenhauser, Carlo, Lim, Heng Keang, Scheers, Ellen, Verboven, Peter, Cuyckens, Filip, Leclercq, Laurent, Evans, David C., Kelley, Michael F., Johnson, Mark D., Snoeys, Jan

“…Aims Canagliflozin is a recently approved drug for use in the treatment of type 2 diabetes. The potential for canagliflozin to cause clinical drug–drug…”
Get full text

Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study by De Jonghe, Sandra, Johnson, Mark D., Mamidi, Rao N.V.S., Vinken, Petra, Feyen, Bianca, Lammens, Godelieve, Proctor, Jim

“…During preclinical development of canagliflozin, an SGLT2 inhibitor, treatment-related pheochromocytomas, renal tubular tumors (RTT), and testicular Leydig…”
Get full text

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants by Devineni, Damayanthi, Vaccaro, Nicole, Murphy, Joe, Curtin, Christopher, Mamidi, Rao N V S, Weiner, Sveta, Wang, Shean-Sheng, Ariyawansa, Jay, Stieltjes, Hans, Wajs, Ewa, Di Prospero, Nicholas A, Rothenberg, Paul

“…Canagliflozin, a sodium-glucose co-transporter 2 inhibitor, approved for the treatment of type-2 diabetes mellitus (T2DM), is metabolized by uridine…”
Get full text

Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin by Mamidi, Rao N.V.S., Proctor, Jim, De Jonghe, Sandra, Feyen, Bianca, Moesen, Esther, Vinken, Petra, Ma, Jing Ying, Bryant, Stewart, Snook, Sandra, Louden, Calvert, Lammens, Godelieve, Ways, Kirk, Kelley, Michael F., Johnson, Mark D.

“…Canagliflozin is an SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. Studies were conducted to investigate the mechanism responsible for…”
Get full text

Successful Integration of Nonclinical and Clinical Findings in Interpreting the Clinical Relevance of Rodent Neoplasia with a New Chemical Entity by Ways, Kirk, Johnson, Mark D., Mamidi, Rao N. V. S., Proctor, James, De Jonghe, Sandra, Louden, Calvert

“…Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, has been developed for the treatment of adults with type 2 diabetes mellitus (T2DM). During…”
Get full text

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants by Devineni, Damayanthi, Manitpisitkul, Prasarn, Vaccaro, Nicole, Bernard, Apexa, Skee, Donna, Mamidi, Rao N V S, Tian, Hong, Weiner, Sveta, Stieltjes, Hans, Sha, Sue, Rothenberg, Paul

“…Drug-drug interactions between canagliflozin, a sodium glucose co-transporter 2 inhibitor approved for the management of type-2 diabetes mellitus, and an oral…”
Get full text